The two healthcare sector stocks with positive return yields and ground-breaking technologies to treat patients are discussed below:
Cynata Therapeutics Limited
The Carlton, Australia-based Cynata Therapeutics Limited (ASX: CYP), formerly known as Eco Quest Limited, was established in 2011. The company, along with its subsidiaries, develops and sells a mesenchymal stem cell technology “Cymerus”, with proprietary rights, for human therapeutic use primarily in Australia; and other products to treat patients with asthma, diabetes, heart attack, brain cancer etc. Its flagship product is CYP-001, undergoing Phase I clinical trial to treat the graft versus host disease. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
Over the years, Cynata has forged multiple partnerships with organisations and educational institutions including University of Sydney, Monash University, Department of Neurosurgery at Brigham and Women’s Hospital at the Harvard Medical School, Critical Care Research Group etc.
The CYP stock is listed on the Australian Securities Exchange (ASX) with a market capitalisation of AUD 153.68 million and ~100.77 million outstanding shares. With the close of the trading session on February 11th, 2019, the stock was trading at a market price of AUD 1.560, up 2.295% indicating an intra-day gain of AUD 0.035. Over the last six months, the stock has generated a positive return yield of 27.08% as well as a YTD of 20.08%.
At the end of January 2019, the company reported Completion of the Clinical Study Report (CSR) for Phase 1 Trial of CYP-001 in GvHD and funding sanction from the National Health and Medical Research Council (NHMRC) for Phase 2 trial of Cynata’s Cymerus™ mesenchymal stem cells (MSCs) in patients with osteoarthritis.
The Lane Cove, Australia-based Nanosonics Limited (ASX: NAN), established in 2000, is engaged in R&D and commercialisation of infection control and decontamination products and allied technologies. Its products include ultrasound probe disinfector “trophon EPR” and ultrasound probe high-level disinfection device “trophon2”. In addition, it also offers trophon EPR and trophon2 consumables and accessories such as ding NanoNebulant cartridges, trophon printers, chemical indicators, logbooks, and several others. It has operations across North America, Australia, Europe, and the Asia Pacific.
The NAN stock is listed on the ASX with a significant market capitalisation of AUD 1.02 billion and approximately 299.88 million outstanding shares. With the close of the trading session on February 11th, 2019, the NAN stock was trading at a market price of AUD 3.410, up 0.294%, indicating an intra-day gain of AUD 0.010. Around 659,321 volume of shares were traded.
Over the previous six months, the stock has generated a positive return yield of 3.34%. The trend continued in 2019 with a YTD of 22.30%, indicating a sustained uptrend in the stock price. The stock has a 1-year high of AUD 3.860 and a 1-year low of AUD 2.260.
In the 2018 half-year financial results report for the period ended December 31st, 2017, (H1 2018), the company posted operating profit before tax at $ 3.7 million, up 3% on prior half while cash reserves were recorded at $ 66.5 million, up from $ 63.0 million at June 30th, 2017, maintaining a strong balance sheet to support its future endeavours.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.